Amgen's Plea To Stop Zarxio Launch Denied; Next Move?
This article was originally published in Scrip
Executive Summary
In a brief order on Sept. 2, a three-judge panel from the US Court of Appeals for the Federal Circuit denied Amgen's "emergency" motion for an injunction to stop Novartis unit Sandoz from launching its biosimilar Zarxio (filgrastim-sndz).